Other studies supporting the result of decreased MACE incidence with SGLT2 inhibitors included results from the CANVAS Program, which showed that diabetic participants with ASCVD or CV risk factors had significantly fewer MACE incidences while on 100 mg or 300 mg of canagliflozin compared to placebo, HR 0.86; 95% CI (0.75-0.97) [6]. The gene discussed is SLC5A2; the disease is atherosclerosis.